Bellicum Pharmaceuticals — Investor Presentation (February 2021)
25 slides from Bellicum Pharmaceuticals's investor presentation, Feb 9, 2021

Slide 1: Building a powerful new future in cellular IO
Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO February 2021Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO February 2021

Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, and related technologies; our product candidates including BPX-601, BPX-603, and

Slide 3: Building a Powerful New Future in Cellular IO
Building a Powerful New Future in Cellular IO Our GoCAR platform is engineered to break through the limitations of current cell therapies Persistence Proliferation Enhances effector cell Boosts effector cell functional persistence by proliferation and extends resisting exhaustion and survival, poten

Slide 4: Product Pipeline
Product Pipeline Establishing the clinical value of GoCAR-T in solid tumors to propel cellular IO forward Clinical Product Candidate Discovery IND-Enabling Proof-of-Concept BPX-601 PSCA+ Pancreatic Cancer Castration-Resistant Prostate Cancer PSCA GoCAR-T BPX-603 HER2+ Solid Tumors HER2 GoCAR-T (Dual

Slide 5: Technology Overview
Technology Overview 5Technology Overview 5

Slide 6: GoCAR: Differentiated Technology Platform
GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC” 6GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC” 6

Slide 7: GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion
GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion iMC activation limits T cell dysfunction in repeat tumor stimulation exhaustion assay T cell IL-2 production T cell expansion HER2+ 100 100000 tumor cells BPX-603 + Rim 10000 BPX-603 + Rim NT NT 1000 Repeat HER2.z HER2.z 10

Slide 8: GoCAR Persistence: Resistance to Immune Suppressive TME
GoCAR Persistence: Resistance to Immune Suppressive TME iMC overrides common inhibitory molecules in the tumor microenvironment TGF-b PD-L1 Inhibitory TME 140 35 BPX-601 + Rim BPX-601 + Rim 120 30 M2 MF 25 100 PGE MDSC 2 80 BPX-601 20 BPX-601 BPX-601 + PD-L1 BPX-601 + TGF-b 60 15 PD-L1 BPX-601 + TGF

Slide 9: BPX-601 PSCA GoCAR-T
BPX-601 PSCA GoCAR-T 9BPX-601 PSCA GoCAR-T 9

Slide 10: BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA
BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA Unmet Need Product Profile Summary High unmet need in solid tumors expressing ▪ Attractive first-in-class solid tumor CAR-T opportunity prostate stem cell antigen (PSCA) ▪ First-in-human experience with iMC Annual Annual % Expressing Status Update

Slide 11: BPX-601: Phase 1/2 Trial
BPX-601: Phase 1 Trial Dose escalation in relapsed/refractory pancreatic cancer Dose Standard Lead-in Repeat Rimiducid Lead-In & Dose Escalation Escalation Conditioning (Cohort 0) (Cohort 5C) (Cohorts 3, 4, 5A) (Cohort 5B) Conservatively designed to evaluate safety • Lead-in cohort with cells only P

Slide 12: BPX-601: Safety Reported Through Cohort 5C
BPX-601: Safety Reported Through Cohort 5C Updated based on data cut December 1, 2020* Cohort 0 Cohort 3 Cohort 4 Cohort 5A Cohort 5B All Patients Cohort 5C Patients, n (%) n = 3 n = 3 n = 3 n = 4 n = 5 n = 5 n = 23 Any AE 3 (100) 3 (100) 3 (100) 4 (100) 5 (100) 5 (100) 23 (100) ▪ Adverse events (AE

Slide 13: BPX-601: Updated Efficacy Through Cohort 5C
BPX-601: Updated Efficacy Through Cohort 5C Updated based on data cut December 1, 2020* Anti-tumor Activity in ITT Population Cohort 0 Cohort 3 Cohort 4 Cohort 5A Cohort 5B Overall Cohort 5C Patients, n (%) n = 3 n = 3 n = 3 n = 4 n = 5 n = 5 n = 23 Progressive Disease (PD), n 2 1 1 1 2 1 8 Stable D

Slide 14: Interim Biomarker Update: BPX-601 Cohort 5C
Interim Biomarker Update: BPX-601 Cohort 5C Evidence of repeat rimiducid-mediated CAR-T cell activation was observed • Rimiducid administration was associated with increased serum cytokine levels, including IL-5, TNF-�� , and IFN-�� • Rimiducid treatment was also associated with increased expression

Slide 15: BPX-601: GoCAR-T Increased Immunomodulatory Cytokines
BPX-601: GoCAR-T Increased Immunomodulatory Cytokines Infusion of BPX-601 and activation with rimiducid increased immunomodulatory cytokines ▪ Increases in Th1 and Th2 cytokines were observed with: ▪ Administration of BPX- 601 GoCAR-T cells ▪ GoCAR-T activation with rimiducid Shaw et al, ASCO GI 202

Slide 16: BPX-601: GoCAR-T Infiltrated Metastatic Pancreatic Tumors
BPX-601: GoCAR-T Infiltrated Metastatic Pancreatic Tumors On-treatment biopsies taken from metastatic lesions show BPX-601 tumor infiltration BPX-601 Infiltration 5 0 0 ▪ Analysis of tumor metastases from patients 4 0 0 212 showed: T u m o r 3 0 0 ▪ Infiltration of BPX-601 S t r o m a 161 GoCAR-T ce

Slide 17: BPX-601: Modulation of Tumor Microenvironment
BPX-601: Modulation of Tumor Microenvironment Changes in gene expression consistent with productive T cell immune responses ▪ Upregulation of T/CAR-T cell Differentially Expressed Genes in Tumor Metastases After BPX-601 + Rim associated genes including: (Cohort 5B, n=3) ▪ GZMB – Target cell killing

Slide 18: BPX-603 HER-2 GoCAR-T
BPX-603 HER-2 GoCAR-T 18BPX-603 HER-2 GoCAR-T 18

Slide 19: BPX-603 Dual Switch GoCAR-T Targeting HER2
BPX-603 Dual Switch GoCAR-T Targeting HER2 Product Profile Summary Unmet Need 5-year OS ▪ HER2 is a validated tumor antigen expressed on numerous 1 + Indication Incidence HER2 1 (Stage IV) solid tumors with high unmet need 3 Gastric 28,000 10-30% <20% ▪ BPX-603 designed to potentially address limita

Slide 20: Historical HER2 Studies: Modest Clinical Outcomes
Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥

Slide 21: BPX-603: Compelling Preclinical Evidence
BPX-603: Compelling Preclinical Evidence iMC co-activation enhances cell proliferation Moderate affinity scFv enhances relative to current CAR-T standards anti-tumor effect relative to low affinity FRP5 Tumor growth T cell bioluminescence 10000000 100 10 1000000 BPX-603 + Rim NT 1 FRP5 + Rim 100000

Slide 22: BPX-603 Phase 1/2 Trial Design
BPX-603 Phase 1/2 Trial Design Two-Part Safety/Activity Study of HER2-Targeted Dual Switch GoCAR-T Cells in Previously Treated HER2+ Solid Tumors Phase 2: Multi-Arm Dose Expansion in Select Tumor Types Phase 1: 3+3 Dose Escalation Cohort 1: Gastric • Expansion cohorts 10 patients each Locally advanc

Slide 23: Summary
Summary 23Summary 23

Slide 24: Anticipated Key Program Goals & Milestones
Anticipated Key Program Goals & Milestones Goals & Milestones Planned Timing BPX-601 1Q'22 Phase 1 data update in mCRPC Initial Phase 1 data 2H’21 BPX-603 24Anticipated Key Program Goals & Milestones Goals & Milestones Planned Timing BPX-601 1Q'22 Phase 1 data update in mCRPC Initial Phase 1 data 2H

Slide 25: Investment Summary
Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance BPX-601 BPX-603 • Autologous GoCAR-T targeting PSCA• Au
Source: SEC EDGAR · 8-K filed Feb 9, 2021
More decks from Bellicum Pharmaceuticals Inc
Investor Presentation (December 2021)28 slides · Dec 6, 2021
Investor Presentation (September 2021)28 slides · Sep 13, 2021
Investor Presentation (October 2020)26 slides · Oct 29, 2020
Investor Presentation (January 2020)29 slides · Jan 15, 2020
Investor Presentation (July 2019)29 slides · Jul 29, 2019
Investor Presentation (June 2019)31 slides · Jun 4, 2019